SUPERNUS PHARMACEUTICALS, INC. Operating Lease, Weighted Average Discount Rate, Percent
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Operating Lease, Weighted Average Discount Rate, Percent of 5.30% as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-03-02
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 5.30%.
- 2024-12-31: Operating Lease, Weighted Average Discount Rate, Percent 4.90%.
- 2023-12-31: Operating Lease, Weighted Average Discount Rate, Percent 4.50%.
- 2022-12-31: Operating Lease, Weighted Average Discount Rate, Percent 3.80%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2025-12-31 | 5.30% 10-K · filed 2026-03-02 | |
| 2024-12-31 | 4.90% 10-K · filed 2026-03-02 | |
| 2023-12-31 | 4.50% 10-K · filed 2025-02-25 | |
| 2022-12-31 | 3.80% 10-K · filed 2023-03-09 | |
| 2021-12-31 | 3.71% 10-K · filed 2022-04-13 | |
| 2020-12-31 | 4.33% 10-K · filed 2021-03-08 | |
| 2020-03-31 | 4.30% 10-Q · filed 2020-05-15 | |
| 2019-12-31 | 4.40% 10-Q · filed 2020-05-15 | 4.39% 10-K · filed 2020-02-28 |
| 2019-09-30 | 4.34% 10-Q · filed 2019-11-08 | |
| 2019-06-30 | 4.36% 10-Q · filed 2019-08-09 | |
| 2019-03-31 | 4.37% 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |